Avacta Group Plc logo

Avacta Group Plc(LSE) AVCT

Market Cap£326.15MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2006)-83%
5 Year-46%
1 Year-2%
1 Month-13%
£0.69
+2.97%
+0.02Today
Avacta Group Plc last closing stock price
MetricPriceDate
Last closeGBX 67.552026-10-19
Avacta Group Plc stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+5.55%GBX 64.002026-10-12
1 month-13.4%GBX 78.002026-09-18
3 month+0.82%GBX 67.002026-07-21
Year to date+16.47%GBX 58.002025-12-31
1 year-2.1%GBX 69.002025-10-17
3 year-48.04%GBX 130.002023-10-20
5 year-46.37%GBX 125.962021-10-20
Since inception-83.03%GBX 3.952006-08-11

Avacta Group Plc Financials at a Glance

Market Cap

£326.15MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

£226.00K

Net Income (TTM)

-£102.98M

EPS (TTM)

-£0.09

P/E Ratio

-7.15

Dividend

£0.00

Beta (Volatility)

0.08 (Low)

Price

£0.69

Volume

1,623,292

Open

£0.67

Previous Close

£0.69

Daily Range

£0.66 - £0.69

52-Week Range

£0.48 - £0.91

Estimated Earnings Date

Apr 22, 2027

AVCT News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Avacta Group Plc

Avacta Group Plc operates as a clinical-stage biopharmaceutical company, specializing in the development of cancer therapies and diagnostic solutions. The company leverages its proprietary Affimer and pre|CISION technology platforms to drive advancements in healthcare across the United Kingdom, North America, South Korea, and broader regions of Asia and Europe.

Products and Services
  • Development of bespoke Affimer proteins for customer products
  • Internal diagnostic assays, including the AffiDX SARS-CoV-2 rapid antigen test
  • Innovative cancer immunotherapies utilizing proprietary technologies
Growth Outlook
  • Strategic partnerships with LG Chem Life Sciences and Tufts University enhance research capabilities
  • Expansion into new markets in Asia and Europe supports long-term growth potential
  • Continued investment in R&D aims to advance novel therapeutic solutions
Financial Highlights
  • Recent quarterly revenue of £57,000 reflects ongoing development phase
  • Trailing twelve months (TTM) net income shows a loss of £13.4 million
  • Cash and cash equivalents at £16.8 million provide operational runway
Avacta Group Plc is positioned at the forefront of biopharmaceutical innovation, focusing on both diagnostics and therapeutics. The company's proprietary technologies, particularly the Affimer platform, offer unique solutions in the healthcare sector. With a robust pipeline and strategic collaborations, Avacta aims to enhance its market presence and drive future growth. Despite current financial challenges, including a significant net loss, the company maintains a solid cash position, allowing for continued investment in research and development. The ongoing partnerships and expansion efforts indicate a commitment to long-term success in the competitive biotechnology landscape.
AI Generated • Sep 24, 2026

Industry

Biotechnology

CEO

Christina Marie Coughlin, MD, PhD

Headquarters

London, GL W12 7RZ, GB

AVCT Financials

Key Financial Metrics (TTM)

Gross Margin

-876.11%

Operating Margin

-28092.04%

Net Income Margin

-35730.97%

Return on Equity

-1293.07%

Return on Capital

-173.94%

Return on Assets

-130.49%

Earnings Yield

-13.99%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

£326.15MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

486.79M

Volume

1.62M

Avg. Volume

1.35M

Financials (TTM)

Gross Profit

-£4.61M

Operating Income

-£62.54M

EBITDA

-£54.52M

Operating Cash Flow

-£50.31M

Capital Expenditure

-£105.00K

Free Cash Flow

-£50.41M

Cash & ST Invst.

£20.27M

Total Debt

£19.86M

Avacta Group Plc Performance Analysis

Avacta Group Plc annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31GBP 9,653,000228.2%
20232023-12-31GBP 2,851,000-70.5%
20242024-12-31GBP 113,000-96.0%
20252025-12-31GBP 113,0000.0%
Avacta Group Plc sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-311.8%
Q22025-06-30-1.8%
Q42025-12-311.8%
Q22026-06-30-1.8%
Avacta Group Plc annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31GBP -0.1437.2%
20232023-12-31GBP -0.12-15.6%
20242024-12-31GBP -0.1525.7%
20252025-12-31GBP -0.10-37.4%
Avacta Group Plc sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-31-71.5%
Q22025-06-3032.5%
Q42025-12-31-10.6%
Q22026-06-3013.5%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

£56.00K

+0.0%

Gross Profit

-£506.00K

-116.6%

Gross Margin

-9.04%

N/A

Market Cap

£326.15MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

£4.03M

N/A

Employees

81

N/A

Net Income

-£19.02M

-52.5%

EBITDA

-£14.04M

-140.6%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

£20.27M

-37.7%

Total Debt

£19.86M

-35.1%

Accounts Receivable

£5.40M

-28.8%

Inventory

£0.00

-100.0%

Long Term Debt

£0.00

-100.0%

Short Term Debt

£19.86M

-21.0%

Return on Assets

-1.30%

N/A

Return on Invested Capital

-8.34%

N/A

Free Cash Flow

-£14.30M

-9.8%

Operating Cash Flow

-£14.28M

-15.9%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
SCLP.LScancell Holdings plc
£0.09+0.00%
FARN.LFaron Pharmaceuticals Oy
£0.35-2.78%
SAR.LSareum Holdings plc
£0.28+0.01%
IMM.LImmuPharma PLC
£0.04+3.90%

Trending Stocks

Symbol / CompanyPricePrice Chg
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$98.44+5.09%
CRWVCoreWeave
$59.65-2.83%
INTCIntel
$92.09+2.49%
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$46.74-5.06%

Questions About AVCT

What is the current price of Avacta Group Plc?

Avacta Group Plc is trading at £0.69 per share.

What is the 52-week range for Avacta Group Plc?

Over the past 52 weeks, Avacta Group Plc has traded between £0.48 and £0.91.

How much debt does Avacta Group Plc have?

As of the most recent reporting period, Avacta Group Plc reported total debt of £17.71M.

How much cash does Avacta Group Plc have on hand?

Avacta Group Plc reported £16.86M in cash and cash equivalents in its most recent financial results.

What is Avacta Group Plc’s dividend yield?

Avacta Group Plc does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.